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Abstract
Research on combining pro- and prebiotics as synbiotics to enhance human
and animal health has accelerated in the past 10 years, includingmany clinical
trials that have assessed a diverse range of synbiotic formulations. In this
review, we summarize these studies as well as the commercial applications
of synbiotics that are available. In particular, we critically assess the claimed
health benefits of synbiotic applications and the ecological and therapeutic
factors to consider when designing synbiotics and discuss the implications
of these concepts for future research in this field.
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FUNCTIONAL IMPORTANCE OF THE COLONIC MICROBIOTA
The human gastrointestinal (GI) tract is colonized by approximately 1014 microbial cells, with the
majority (1011–1012 cells/g) residing in the colon and fewer than 102–103 cells/g in the stomach and
proximal ileum (Sartor 2008, Vyas & Ranganathan 2012). This microbiota serves several critical
physiological functions. It protects the host from infection by invasive pathogenicmicroorganisms
by competing with them for nutrients and niches (Belkaid & Hand 2014, Stecher & Hardt 2008,
Yasmin et al. 2015) and producing antimicrobial substances, including bacteriocins and other
antagonistic peptides and small molecules (Buffie & Pamer 2013, Jonkers 2016). In addition, the
microbiota aids in the development of the adaptive and innate immune systems; produces essential
vitamins, amino acids, and other metabolites; and facilitates utilization of nutrients, especially
polymeric carbohydrates (Walsh et al. 2014). Finally, the microbiota contributes caloric energy
to the host. Assuming a typical European diet, the gut microbiota can potentially yield as much as
140–180 kcal/day via fermentation of the 50–60 g of carbohydrates that escape host metabolism
(McNeil 1984).
The extent and rate of carbohydrate digestion and utilization in humans depend primarily on
anatomical location. Initially, carbohydrates are hydrolyzed in the mouth via amylases, and starch
and glycogen are further hydrolyzed into simple sugars, which are absorbed in the small intestine.
In the large intestine, indigestible substrates, including various dietary fibers and carbohydrates,
are hydrolyzed and fermented by bacteria. The colon offers a favorable environment for anaerobic
microbes, with high quantities of nutrients that escape host digestion, a thick mucus layer secreted
by a high number of Goblet cells, reduced intestinal motility, and a favorable pH (Wlodarska
et al. 2015). Because approximately 70% of the constituents of the gut microbiota reside in the
large intestine, these organisms may have a profound effect on energy storage, host metabolism,
and intestinal health (Vyas & Ranganathan 2012). The proximal part of the large intestine is
responsible for most of the absorption of the short-chain fatty acids (SCFAs; mainly acetate,
butyrate, andpropionate) that are producedby the colonic bacteria fromfiber fermentation at a rate
of approximately 0.5–0.6 mole/day (Angelakis & Lagier 2016,McNeil 1984, Vyas &Ranganathan
2012), depending on the microbiota composition, nature of the fermentable carbohydrate, and
dietary intake ( Jonkers 2016).
SCFAs have several beneficial effects on host health (Puertollano et al. 2014, Tan et al. 2014),
and as the preferred energy source for colonocytes (Suzuki et al. 2008), SCFAs promote epithelial
integrity (Tan et al. 2014). Additionally, SCFAs affect the thickness of the mucus layer, support
epithelial cell survival, and regulate expression of tight junction proteins ( Jonkers 2016, Krishnan
et al. 2015). Disruption of gut integrity has been attributed to serious intestinal diseases, includ-
ing celiac disease, inflammatory bowel disease (IBD), and colorectal cancer (Den Besten et al.
2013, Puertollano et al. 2014, Tolhurst et al. 2012). The local and systemic immunomodulatory
properties of SCFAs include the suppression of NF-κB activity (Park et al. 2007, Tedelind et al.
2007, Vinolo et al. 2011). In addition, SCFAs exhibit anti-inflammatory properties by modulating
immune cell chemotaxis, reactive oxygen species, and cytokine release (Tan et al. 2014). SCFAs
also regulate colonic mobility and blood flow and can influence colon pH, which has a direct
impact on the uptake and absorption of nutrients and electrolytes (Tazoe et al. 2008).
Butyrate formation by the colonic microbiota is of particular interest, as this compound has
been shown to havemultiple biological effects. Butyrate has anti-inflammatory properties, inhibits
interleukin (IL)-12, and upregulates IL-10 in monocytes (Hamer et al. 2008, Park et al. 2007). In
addition, butyrate (among other SCFAs) has signaling capacities via G protein–coupled receptors
(Brown et al. 2003, Kasubuchi et al. 2015, Krishnan et al. 2015, Tang et al. 2011, Tolhurst et al.
2012) and increases levels of anorectic hormones such as PYY andGLP-1 that contribute to energy
metabolism and appetite control ( Jonkers 2016). Butyrate also induces apoptosis of neutrophils
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(Aoyama et al. 2010) and has anticancer activity in several human cell lines (Foglietta et al. 2014,
Wang et al. 2013, Yamamura et al. 2014).
The impact of GI microbiota on the health of humans and animals is now one of the most-
studied fields in biology and medicine. Although the medical importance of the GI microbiota has
been recognized for more than a century, multi-omics technologies now provide tools necessary
to gain a community-wide, high-throughput assessment of this complex microbial ecosystem.
Discoveries made during the past 20 years have dramatically changed the way that clinicians and
researchers associate the gut microbiota with both nutrition and medicine. In particular, it is now
becoming possible to establish mechanisms by which the gut microbiota interacts with the host
and thereby alters microbiota composition and activity of the GI microbiota. Although it remains
difficult to establish cause-and-effect relationships in humans, research in animalmodels has clearly
established that the GI microbiota, and alterations thereof, contribute to several pathologies.
Thus, although the microbiota provides many beneficial effects for the host, the composition
of an individual’s microbiota may also predispose that individual to certain intestinal as well as
systemic diseases, including obesity and diabetes.
The strong associations of the composition, function, and dysbiotic patterns of the GI micro-
biota with a wide range of pathologies provide a rationale for modulation of the microbiota to
improve human health (Flint et al. 2012, Frank & Pace 2008, Lemon et al. 2012, Marchesi et al.
2015). Several strategies to achieve this goal have been explored, including modifying the diet
and dietary components and the use of prebiotics and probiotics. Although the GI microbiota in
healthy humans is generally resistant to these therapeutic interventions, they all have the potential
to alter the microbiota to some extent.
MODULATION OF THE GUT MICROBIOTA WITH PRO-, PRE-,
AND SYNBIOTICS
Among the first strategies proposed to modulate the gut microbiota was the administration of
live microbes. Indeed, what we now call probiotics have been produced and consumed for more
than 100 years (Kolida & Gibson 2011, Mechnikoff 1908), long before the term was formally
defined. Probiotics are currently defined as “live microorganisms that, when administered in ade-
quate amounts, confer a health benefit on the host” (Hill et al. 2015, p. 506). There are hundreds
of probiotic strains and products in the marketplace, and many clinicians recommend probiotics
to patients for a variety of conditions, including antibiotic-associated diarrhea, acute gastroen-
teritis, general GI disorders [such as irritable bowel syndrome (IBS) and infant colic], and mild
ulcerative colitis (UC), and to improve lactose digestion (Sanders 2015). Systematic reviews and
meta-analyses have shown that probiotics may aid the treatment of antibiotic-associated diarrhea
(D’Souza et al. 2002); prevention of necrotizing enterocolitis in preterm neonates (Deshpande
et al. 2010); induction of remission and maintenance of IBD (Shen et al. 2014); prevention and
control of hyperglycemia (Ruan et al. 2015); improvement in levels of total cholesterol, high-
density lipoproteins (HDLs), and tumor necrosis factor (TNF)-α in patients with nonalcoholic
fatty liver disease (NAFLD) (Gao et al. 2016); and reduction of glucose and insulin as well as
a homeostatic model assessment of insulin resistance in diabetes patients (Sun & Buys 2016).
Jonkers (2016) also reports the effectiveness of probiotics for preventing or reducing the severity
of infectious and antibiotic-associated diarrhea and respiratory tract infections.
Despite this extensive scientific literature, no health claim for probiotics has been approved in
Europe or the United States by the responsible regulatory agencies [European Food Safety Au-
thority (EFSA) andUS Food andDrug Administration (FDA)]. In contrast, Canada has accepted a
limited number of non-strain-specific claims about the general nature of probioticmicroorganisms
(http://www.inspection.gc.ca), as has Japan (Farnworth 2008).
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In contrast to the century-old history of probiotics, the prebiotic concept was formally intro-
duced only in 1995. Defined originally as “a nondigestible food ingredient that beneficially affects
the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria
in the colon, and thus improves host health” (Gibson & Roberfroid 1995), the current criteria
for the definition of prebiotics are now the subject of considerable debate (Bindels et al. 2015a,
Hutkins et al. 2016, Katsnelson&Writer 2016, Valcheva&Dieleman 2016). Although the general
requirements of a prebiotic have been retained in the most recently proposed definition (Gibson
et al. 2017), some key elements of the definition, including specificity and selectivity, have been
questioned (Bindels et al. 2015a). The Canadian Food Inspection Agency has now established its
own definition for prebiotics, but neither the FDA nor the EFSA currently provides a definition.
The most widely studied prebiotics are the simple fructans and galactans, available commer-
cially as inulins, fructooligosaccharides (FOSs), and galactooligosaccharides (GOSs). A variety of
other oligosaccharides, including isomaltooligosaccharides, mannan oligosaccharides, pectins, re-
sistant starches, xylooligosaccharides, arabinoxylans, and human and bovinemilk oligosaccharides,
have also been studied for their potential prebiotic properties (Krumbeck et al. 2016). Prebiotics
are suggested to provide health benefits through several differentmechanisms, including composi-
tional or metabolic changes to the resident microorganisms, stimulation of growth and/or activity
of putative health-promoting bacteria, and production of SCFAs (Verspreet et al. 2016). SCFAs
reduce the local pH, induce the production of immunomodulatory cytokines, and stimulate mucin
production (Preidis & Versalovic 2009).
Some prebiotics are reported to have fermentation-independent health effects; for example,
human milk oligosaccharides may protect infants from infections by inhibiting adherence of
pathogens to the epithelial cells that line the GI tract (Yu et al. 2016). Similar effects have been
reported for GOSs (Quintero-Villegas et al. 2014). Recently, microbiota-independent effects of
resistant starch on improved insulin sensitivity and other metabolic benefits have been reported
(Bindels et al. 2017). Similarly, systematic meta-analyses have shown that prebiotic treatments
can reduce fasting insulin levels (Beserra et al. 2015), aid in the treatment of diarrhea (Zaman
& Sarbini 2015) and other infectious diseases (Lohner et al. 2014), and restore bowel function
(Collado Yurrita et al. 2014). There are also reports that prebiotics may contribute to abdominal
pain, diarrhea, and increased production of gas depending on the doses, nature of the prebiotic,
and susceptibility of the host ( Jonkers 2016).
SYNBIOTIC CONCEPTS AND DEFINITIONS
When Gibson & Roberfroid (1995) first articulated the prebiotic concept more than 20 years
ago, they also envisioned that pre- and probiotics could be combined as synbiotics. Later, Kolida
& Gibson (2011) described the two general ways synbiotics could enhance the effects of their
component parts. Complementary synbiotics are those that contain pro- and prebiotics chosen
independently of one another, with each responsible for a particular effect or health benefit. Ac-
cordingly, the best-case scenario for such a synbiotic is that each constituent, namely, the pro- and
prebiotic, would have a beneficial effect and the effects would be additive. In this complementary
approach, the prebiotic component is not necessarily preferentially fermented by the probiotic
strain and could theoretically support other members of the GI microbiota. The probiotic strain
would gain no ecological advantage by being combined with the prebiotic and indeed may not be
capable of fermenting the substrate at all.
In contrast, synergistic synbiotics also consist of a probiotic strain and a prebiotic substrate,
but the difference is that the prebiotic is specifically intended to support the growth of the cognate
probiotic (Kolida &Gibson 2011). Accordingly, there is no requirement for other members of the
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gut microbiota capable of fermenting the prebiotic to be present. It is well known in the clinical
diet/microbiota literature that response phenotypes are highly individual, with a portion of test
subjects failing to respond to treatment (Cook et al. 2016, Korpela et al. 2014, Salonen et al.
2014, Serrano-Villar et al. 2017). As described below, synergistic synbiotics have the important
advantage of addressing nonresponder outcomes by providing both the strain and its growth
substrate in situ.
RATIONALE FOR SYNERGISTIC SYNBIOTICS
When prebiotics are introduced with a probiotic strain that does not ferment the substrate in vitro
or does so slowly in vivo, the outcomemay be highly unpredictable and would likely depend on the
composition of an individual’s gut microbiota. As noted above, it is apparent from human clinical
studies that a bifidogenic response or other changes in the microbiota following prebiotic supple-
mentation occurs in some subjects but not in others. The nature of the responder/nonresponder
phenotype (i.e., what makes a responder a responder) remains the subject of considerable interest.
Davis et al. (2011) suggested that bacterial strains capable of fermenting GOSs or other prebiotics
in the colon might be absent in the nonresponder population. Similarly, the inability of specific
gut microbes to outcompete other members of the gut microbiota could also affect the responder
status of subjects. Indeed, Davis et al. (2011) showed that even a high abundance of taxa that would
be expected to ferment a given prebiotic substrate was not a reliable predictor of whether or not
the prebiotic causes a shift in abundance of that taxa.
The variable response to prebiotics has been observed in other studies. Salonen et al. (2014)
showed that obese male individuals on a resistant starch diet could be divided into responders
and nonresponders based on the shifts in the composition of their gut microbiota, and in this
case, a high microbial diversity correlated with a low dietary responsiveness. Similarly, Martı´nez
et al. (2010) have reported a microbial responder and nonresponder phenotype in normal-weight
human subjects who had consumed resistant starches. Kovatcheva-Datchary et al. (2015) divided
their study cohort into responders versus nonresponders based on their metabolic response to a
barley kernel–based bread. A subsequent analysis of the gut microbiota of both groups showed
that the Prevotella to Bacteroides ratio was significantly higher in the responder group.
Predicting whether or not a given subject will be a responder and ultimately obtain a beneficial
health effect from a prebiotic is difficult. Response to treatment depends not only on the functional
and taxonomic compositionof the gutmicrobiota but also onhost abiotic factors.The latter include
the nature of the digestive enzymes provided by the host, stomach and intestinal pH, and transit
time, all of which can ultimately affect enrichment of bacterial members, even if a suitable growth
substrate is provided (Martı´nez et al. 2010).
One of the advantages of synergistic synbiotics is that such formulations could address the
responder/nonresponder phenomenon. To become established in the GI tract, a probiotic must
not only secure nutrients and other growth factors but also outcompete the resident microbiota.
By providing the probiotic organism with a niche opportunity in the form of a selectively fer-
mentable prebiotic, the strain is given a competitive advantage. Thus, its competitive fitness can
be significantly increased and its persistence enhanced (Kolida & Gibson 2011). This approach
is consistent with invasion ecology theory, whereby an invading species is successful when it can
exploit novel resources or outcompete commensals for those resources for successful colonization
and establishment (Catford et al. 2009, Costello et al. 2012, Walter et al. 2018).
This theoretical scenario has recently been demonstrated in a human probiotic feeding trial
(Maldonado-Go´mez et al. 2016). In this study, metagenomic analyses revealed that an au-
tochthonous strain of Bifidobacterium longum subsp. longum could colonize subjects only if genes
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Figure 1
Number of publications on the topic of synbiotics over the past 15 years.
that encoded for enzymes involved in the degradation of specific complex carbohydrates were ab-
sent. This study showed that even for autochthonous bacteria that possess the ecological traits to
be successful in the gut, resources are essential for successful colonization, which is in accordance
with ecological theory (Mallon et al. 2015, Walter et al. 2018). For synbiotic applications, this
would suggest that a supply of resources may relax competition (at least temporarily) and provide
the new species with an advantage sufficient to overcome the colonization challenge (Mallon et al.
2015, Walter et al. 2018).
SYNBIOTICS IN PRACTICE
Although there are many publications on synbiotics (more than 140 were published in 2016 alone)
(Figure 1), our literature search revealed little evidence for synergism between pro- and prebiotics
used in human studies (Table 1). Most of these studies included lactobacilli and bifidobacteria
as the probiotic component and inulin, various oligosaccharides, or dietary fibers as the prebiotic
component (Shukla et al. 2011). Although several studies provided evidence for synergism in
animals, only one study in human subjects provided such evidence (Table 1).
There are a variety of reasonswhy synergismbetween a pro- and a prebiotic is rarely observed in
vivo. Most importantly, most synbiotics used in research to date have not been rationally designed
and have instead been formulated on rather arbitrary criteria, such as shelf life, availability, cost,
industrial performance, or other marketing considerations (Crittenden et al. 2006, Govender
et al. 2014). Therefore, in many cases, probiotic strains were used that may not have utilized the
respective prebiotic. Evenwhen in vitro or in situ screenings of synbiotic combinations are applied,
these techniques do not account for the ecological factors that will affect the probiotic strain in
vivo nor how other autochthonousmembers of the gutmicrobiotamay compete with the probiotic
strain for the prebiotic substrate (Davis et al. 2011, Sonnenburg et al. 2010, Ventura et al. 2009). It
can be challenging to identify a prebiotic that will specifically and selectively enhance the probiotic
strain of interest. New strategies to develop synergistic synbiotic combinations now include in vivo
selection of synbiotic combinations (Krumbeck et al. 2015) or multitaxon insertion sequencing
(Wu et al. 2015). The latter uses a transposon library to identify genes encoding for fitness
determinants based on the relative abundance of a gene’s multitaxon insertion sequencing reads in
the output community compared with the input library. This method allows identification of key
fitness features of gut bacterial strains and gene-level characterization of responses to prebiotics
and other dietary interventions.
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Table 1 Synergistic synbiotics reported in the literature
Reference(s)
Probiotic
component Prebiotic component Subjects
Increase in
probiotic
abundance P value Outcome
Tanaka et al.
1983
Bifidobacterium
breve 4006
Transgalactosylated
oligosaccharide
Healthy adults Probiotic: 9–10.2
log/g feces
Synbiotic:
10–10.5 log/g
fecesa
0.05 Not measured
Wang et al.
1999
Bifidobacterium
LaftiTM 8B
Amylomaize BALB/c mice Probiotic: 4.3%
recovery rate
Synbiotic:
27.92%
recovery rate in
feces
0.05 Not measured
Femia et al.
2002
Lactobacillus
rhamnosus
LGGR© +
Bifidobacterium
lactis Bb12
Oligofructose-
enriched inulin
Male F344 rats LGGR©:
Probiotic:
4.8± 3.4× 105
Synbiotic:
21.1± 18×
105 CFU/g
feces
Bb12: Probiotic:
6.1± 8.1× 105
Synbiotic:
8.4± 12×
105 CFU/g
feces
Not
given
Antitumoric
activity in
azoxymethane-
induced
cancer
Ogawa et al.
2005, 2006
Lactobacillus
casei subsp.
casei JCM
1134TM
Dextran BALB/c mice Probiotic:
1× 104 CFU/mg
feces
Synbiotic:
1.4× 106 CFU/
mg fecesa
0.01 Significantly
elevated NK cell
activity in spleen
mononuclear
cells
Krumbeck
et al. 2015
Bifidobacterium
adolescentis
IVS-1
Galactooligosaccharide Male Sprague–
Dawley rats
Probiotic:
7.9± 0.1 log10
cells/g colon
content
Synbiotic:
9.47± 0.2 log10
cells/g colon
content
0.0001 None
aAbsolute microbial numbers are not given in the original publication and have been estimated by the author through careful evaluation of graphs in the
original publication.
Abbreviation: NK, natural killer.
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Gut health 
Treats metabolic syndrome
Decreases risk of colon cancer
Decreases cell proliferation in
colonic tissue
Treats existing tumors
Supports colonization resistance
against pathogens/prevents
GI infections
Prevents/treats IBS and IBD
Improves mucosal structure
Induces alterations in gut microbiota,
leading to altered metabolic activity
(increased SCFAs/bioactive
peptides/organic acid production)
Reduces exposure of intestinal lining
to cytotoxic agents
Improves epithelial barrier function
Alleviates lactose intolerance
Systemic health 
Manages food allergies
Exhibits antioxidant activity
Alters xenobiotic/drug metabolism
Reduces risk of heart disease
Prevents biliary disease
Adjusts blood lipid levels
Stimulates immune system
Suppresses NK cells in
Peyer’s patches
Improves liver function in
cirrhotic patients
Treats hypocholesterolemia
Prevents osteoporosis
Treats asthma/atopy
Supports cholesterol assimilation
Treats hepatic encephalopathy
Treats hypertension
Gut-brain axis 
Treats autism
Reduces stress/depression/anxiety
Supports weight loss
Reduces infant crying
Figure 2
Health claims made for synbiotics in human populations. Abbreviations: GI, gastrointestinal; IBD, inflammatory bowel disease; IBS,
irritable bowel syndrome; NK, natural killer; SCFAs, short-chain fatty acids.
SYNBIOTICS AND THEIR OUTCOMES ON HUMAN HEALTH
IN CLINICAL STUDIES
The reported literature on synbiotics includes a wide range of studies with varying subject groups.
Research subjects have included humans of all ages as well as companion animals (mainly dogs
and cats) and food production animals such as chickens, cows, pigs, cattle, rabbits, and fish (Abdel-
Raheem et al. 2012, Awad et al. 2008, Bengmark 2012, Cerezuela et al. 2011, Hart et al. 2012,
Hasunuma et al. 2011,Gagne´ et al. 2013,Mugambi et al. 2012, Sopkova´ et al. 2017). Rodent animal
models have also been widely used (Asahara et al. 2016, Bindels et al. 2015b, Krumbeck et al. 2015,
Simeoli et al. 2015). In this review, we focus on human clinical studies and the health claims made
for synbiotic combinations to improve human health. It is important to note that despite the
many health claims made for synbiotic combinations in the literature and the commercial market
(Figure 2), no claims have been approved by regulatory agencies in the United States or Europe.
Nevertheless, several meta-analyses and systematic reviews suggest that synbiotic treatments may
provide beneficial health effects (Tables 2 and 3).
There are several challenges involved in evaluating synbiotic clinical studies. As with other
studies on pro- or prebiotics, doses, durations of treatment, targeted populations, and measured
treatment effects are often different, and all can affect measured treatment outcomes. Even the
funding source has been suggested to influence outcomes (Mugambi et al. 2013). There are,
however, considerations unique to synbiotics. In particular, few synbiotic trials consider each
synbiotic component independently; thus, it is not possible to establish whether improvement of
a clinical end point in the synbiotic treatment group was indeed more beneficial than the pro- or
prebiotic treatment alone (Table 4). Therefore, the synbiotic concept cannot be validated in such
cases. Another experimental challenge is to show whether the test strain has become established
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Table 3 Overview of systematic reviews of synbiotic treatments
Reference(s)
Disease
phenotype
Number of
trials/subjects P value Type of synbiotic Subject Outcome
Ghouri et al.
2014,
Saez-Lara
et al. 2015
UC maintenance 1 trial (n = 120) 0.03 Probiotic: BL
Prebiotic: Psyllium
Patients
with UC
IBDQ score:
improved quality
of life
UC induction
and
maintenance
1 trial (n = 41) 0.05 Probiotic: BB
Prebiotic: GOS
Improvement of
endoscopic
grading compared
to standard
therapy group
UC induction 1 trial (n = 18)a,b 0.06 Probiotic: BL
Prebiotic: Synergy
I (I + OF mix)
Sigmoidoscopy
score not
improved
0.05 Inflammatory
markers improved
Management of
CD
1 trial (n = 35) 0.02 Probiotic: BL
Prebiotic: Synergy
I (I + OF mix),
Patients
with CD
Improved clinical
response
compared to
placebo
1 trial (n = 24)a >0.05 Synbiotic 2000
Probiotic: LA2,
PP, LP2, LPSP
Prebiotic: BG, I, P,
RS
No improvement
in endoscopic,
clinical, and
laboratory
parameters
Saez-Lara
et al. 2015
UC 1 trial (n = 10) Not given Synbiotic therapy:
Probiotic: BB,
BL, LC
Prebiotic: psyllium
Patients
with active
CD
Synbiotic is safe
and effective
Fernandes
et al. 2016
Inflammatory
markers in adult
patients with
overweight or
obesity
4 trials (n = 234) Not given Probiotic: LS2,
LC, LR, ST, BL,
LB
Prebiotic: I, FOS
Overweight
or obese
patients
Some synbiotics
and prebiotics
may have im-
munomodulatory
effects
aAlso discussed in Hedin et al. (2007).
bAlso discussed in Zigra et al. (2007).
Abbreviations: CD, Crohn’s disease; IBDQ, inflammatory bowel disease questionnaire; UC, ulcerative colitis.
Probiotic types: BB, Bifidobacterium breve; BL, Bifidobacterium longum; LA2, Lactobacillus affinolactis; LB, Lactobacillus bulgaricus, LC, Lactobacillus casei, LP2,
Lactobacillus plantarum; LPSP, Lactobacillus paracasei subsp. paracasei; LR, Lactobacillus rhamnosus, LS2, Lactobacillus sporogenes; PP, Pediococcus pentosaceus; ST,
Streptococcus thermophilus.
Prebiotic types: BG, β-glucan; FOS, fructooligosaccharide; GOS, galactooligosaccharide; I, inulin; P, pectin; OF, oligofructose; RS, resistant starch.
in the GI tract. Most importantly, strain-specific approaches, which are essential to demonstrate
that the test strain was indeed present, have not been reported.
As noted above, the effectiveness of synbiotic treatments on a range of disease phenotypes has
been summarized by bothmeta-analyses and systematic reviews. In general, however, these reports
are constrained by the small number of studies and disparate composition of the treatments. In the
sections below, recent human trials that applied synbiotics to treat specific clinical disorders are
reviewed individually. These include trials on metabolic syndrome, IBD, diarrhea, colon cancer,
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Table 4 Overview of meta-analyses of synbiotic treatments that combine pro- and synbiotic trials into single analyses
Reference Disease phenotype Outcome
Pitsouni et al. 2009 Patients undergoing abdominal surgery Pro/synbiotic treatment may reduce postoperative infections
after abdominal surgery
Rossi et al. 2012 Patients with chronic kidney disease Limited but supportive evidence for the effectiveness of pre-
and probiotics in reducing uremic toxins. No conclusion about
synbiotics
Zhang et al. 2010 Patients with acute pancreatitis Pre-, pro-, or synbiotic treatment shows no statistically
significant benefit. Safety and efficacy: Use pre-, pro-, or
synbiotics with caution in critically ill patients and patients
with severe acute pancreatitis
Watkinson et al.
2007
Patients admitted to adult intensive care
units
There is currently a lack of evidence to support the use of pre-,
pro-, or synbiotics
He et al. 2013 Patients undergoing colorectal resection
for cancer
Pro/synbiotic administration has a positive effect on the
incidence of diarrhea (P = 0.001), symptomatic intestinal
obstructions (P = 0.008), operative total infections (P =
0.0010), and pneumonia infection (P = 0.04)
Pro/synbiotics administration increases numbers of Lactobacillus
(P < 0.00001) and decreases the counts of Enterobacteriaceae
Dang et al. 2013 Prevention of eczema Pro/synbiotics may reduce incidence of infant eczema.
Prebiotics alone have no effect
Lytvyn et al. 2015 Prevention of postoperative infections
following abdominal surgery in adults
Pro/synbiotics reduce the risk of surgical site infections
compared to placebo or standard of care and have potential
benefits for urinary tract infections with no increased risk of
adverse events. No occurrence of serious adverse events
reported as related to study product
Petrof et al. 2012 Critically ill patients, including burn,
multiple trauma, pancreatic, diarrhea,
general intensive care unit
Clinical trials suggest that probiotics may reduce overall
infection rates in critically ill patients
Chen et al. 2016 Prevention of postoperative infections
following colorectal surgery in adults
Perioperative pro/synbiotics administration is associated with a
significant reduction in total postoperative infectious
complications (P < 0.00001), pneumonia (P = 0.003), wound
infection (P = 0.005), and length of hospital stay (P = 0.009).
No significant differences in the incidence of intra-abdominal
abscess or urinary infection
Arumugam et al.
2016
Decrease of postoperative sepsis in
gastrointestinal surgical patients
Pro/synbiotics significantly reduced risk of postoperative sepsis
by 38% (P < 0.0001)
IBS, and kidney and liver diseases. Only randomized and placebo-controlled trials (RCTs) using
clearly described products are discussed.
Metabolic Syndrome
Metabolic syndrome refers to metabolic aberrancies strongly associated with obesity that collec-
tively contribute to the risk of coronary heart disease and type II diabetes (Cornier et al. 2008).
Risk factors include central obesity, impaired glucose tolerance, dyslipidemia, and hypertension
(Andersen & Fernandez 2013, Van Vliet-Ostaptchouk et al. 2014). Several synbiotic formulations
have been used in clinical trials to assess improvement of metabolic syndrome. Eslamparast et al.
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(2014) conducted a double-blind RCT analyzing the effect of FOSs (250mg) and a probiotic cock-
tail (Protexin R©) of seven different strains (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus
thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, B. longum, and Lactobacillus bulgaricus)
on 38 subjects suffering from metabolic syndrome. Subjects were instructed to consume the sup-
plement or placebo (maltodextrin) twice daily for 28 weeks. They were also instructed to follow
strict dietary recommendations, lower energy intake, and increase physical activity. At the end
of the study, individuals in the synbiotic treatment group had improved levels of insulin resis-
tance, fasting blood sugar, triacylglycerides, and serumHDLs compared to the placebo treatment
group. No difference was observed in body mass index, low-density lipoprotein (LDL) levels, an-
thropometric parameters, and energy intake/expenditure. The authors concluded that synbiotic
treatment can increase the efficacy of a dietary therapy in the management of metabolic syndrome
and insulin resistance. However, an analysis of the gut microbiota was not included, and based on
the study design, it was not possible to confirm that the synbiotic treatment was more effective
than the pro- or prebiotic treatment alone.
A similar synbiotic cocktail was tested for its potential ability to support a weight-loss regime
(Rabiei et al. 2015). Forty-six patients withmetabolic syndrome consumed the synbiotic or placebo
(maltodextrin) twice a day for 12 weeks. All patients experienced significant weight loss, and the
synbiotic treatment reduced systolic blood pressure (P < 0.05). However, 90% of the subjects in
the synbiotic group used medication to reduce blood pressure compared to 75% in the placebo
group before and throughout the duration of the study. The fecal microbiota was not examined,
and the nature of the study design precludes any conclusions about the efficacy of the pre- or
probiotic strains.
The combination of FOSs (3 g) with Lactobacillus plantarum, Lactobacillus delbrueckii, L. aci-
dophilus,L. rhamnosus, andBifidobacterium bifidum (2× 108 CFU total) was assessed in an open-label
RCT. The treatment was provided twice daily for six months to subjects suffering from nonal-
coholic steatohepatitis (Wong et al. 2013). Reductions in intrahepatic triglyceride (P = 0.034)
and serum aspartate aminotransferase (P = 0.008) levels were observed in the synbiotic treatment
group compared to the standard treatment group (n = 10, for each). Again, no assessment of
microbiota was reported.
In healthy adults, the combination of FOSs (10 g) and Lactobacillus salivarius (2× 109 CFU)
significantly reduced total cholesterol, LDL cholesterol, and the concentrations of CRP, IL-6,
and TNF-α compared to the placebo and probiotic-only groups. Further, serum inflammatory
markers and triglycerides were decreased and HDL cholesterol was increased compared to a
placebo after six weeks of treatment (P < 0.05) (Rajkumar et al. 2015). Selective plating was used
to compare the number of Lactobacillus in fecal samples among all three groups. The pro- and
synbiotic treatments significantly increased the number of Lactobacillus compared to the placebo,
but there was no significant difference between the pro- and synbiotic treatments.
A double-blind, parallel-design RCT of 20 healthy subjects found that the synbiotic treatment
of FOSs (10 g) and Ecologic R© 825 (1.5× 1010 CFU) led to significantly more stools, but no
differences in intestinal barrier function (measured by urinary sugar recoveries and ratios; plasma
levels of zonulin, cytokines, and chemokines; and GI symptom scores) were seen compared to
the control group after two weeks of treatment (Wilms et al. 2016). Ecologic R© 825 comprises L.
acidophilus, L. casei, Lactobacillus paracasei, L. plantarum, L. salivarius, Lactococcus lactis, B. bifidum,
and two strains of Bifidobacterium lactis.
Inflammatory Bowel Disease
UC and Crohn’s disease (CD), the two types of IBD, are chronic inflammatory pathologies of
the GI tract. Both conditions occur in individuals who are genetically susceptible and exposed
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to unknown environmental risk factors (Haller et al. 2010). Although the etiology of IBD has
been extensively studied, the disease pathogenesis is not fully known (Goyal et al. 2014). The
characteristics of the inflammation are different in CD and UC, with CD occurring throughout
the GI tract, typically involving the distal small intestine and colon with transmural inflammation
and occasionally associated with granulomas. In contrast, UC inflammation is usually confined to
the mucosa of the colon (Ardizzone & Bianchi Porro 2005, Molodecky et al. 2012). Both UC and
CD are characterized by a relapsing and remitting course leading to a very significant reduction
in quality of life during the disease (Mahida & Rolfe 2004).
Several synbiotic formulations have been used in clinical studies to treat IBD. A combination
of 6 g of inulin/oligofructose (Synergy 1 R©) and 2× 1011 CFU of B. longum was administered to
UC patients (Furrie et al. 2005). The test strain had been isolated from a healthy human subject
and assessed for its aerotolerance, acid tolerance, resistance to bile salt, and adherence to epithelial
cells. Its ability to use the prebiotic substrate as an energy source was also established in vitro.
The organism was further shown to alter the cytokine expression in an HT29 epithelial cell
line and reduce proinflammatory cytokine levels in vitro. For the clinical study, 18 patients were
divided into synbiotic and placebo groups, each receiving the respective treatments twice daily for
4 weeks. The synbiotic treatment led to reduced inflammation and regeneration of epithelial tissue
compared to the placebo group, reducedmRNA levels of humanβ-defensins, and lowered levels of
TNF-α and IL-1α. Although survival of the probiotic strain was not measured in a strain-specific
manner, bifidobacteria-specific rRNA levels increased 42-fold in the synbiotic group compared to
approximately fivefold in the placebo group. This study, however, did not investigate the effects
of the probiotic independently.
Another clinical trial used a synbiotic comprising psyllium (8 g) and a B. longum strain (2×
109 CFU) (Fujimori et al. 2009). Although psyllium is not ordinarily considered a prebiotic, it has
prebiotic status in Japan (Tanaka et al. 2004). Subjects (n = 120) were UC outpatients. This trial
included probiotic- and prebiotic-only treatment groups in the study design. Although most mea-
sured blood markers showed no differences among the three treatments, C-reactive protein was
significantly decreased (P = 0.04) and total protein levels increased (P = 0.03) in blood samples
from the synbiotic group. Hemoglobin and hematocrit increased only in the probiotic group (P =
0.04).Total IBDquestionnaire scores showed significant improvement only in the synbiotic group.
Based on these quality-of-life questionnaires, the investigators concluded that the synbiotic treat-
ment led to a greater quality of life than the pre- or probiotic treatments alone. However, mecha-
nisms responsible for this improvement and survival rates for the probiotic were not determined.
In another clinical study, the effect of a synbiotic containing GOSs (5 g) and B. breve (1×
109 CFU) on subjects with mild to moderate UC was assessed (Ishikawa et al. 2011). Forty-
one patients were treated with either a placebo or the synbiotic for one year. End points in-
cluded endoscopic scores and myeloperoxidase levels in lavage solutions; both were significantly
lower in the synbiotic-treated group. An analysis of the fecal microbiota by plate counting was
also performed for subjects in the synbiotic group before and after the treatment. Of all as-
sessed microbes, only Bacteroidaceae were significantly decreased after the synbiotic treatment.
The abundance of Bifidobacterium remained the same, and B. breve was only detected (5.75 ±
1.65 log10 CFU/g feces) by culturing after the treatment. Therefore, it can be concluded that B.
breve survived passage through the GI tract. Whether or not the applied prebiotic was supporting
the probiotic could not be determined from this study. Interestingly, no bifidogenic effect was
observed due to GOS treatment. This is contrary to results previously reported (Akiyama et al.
2015, Azcarate-Peril et al. 2017, Davis et al. 2010).
In a double-blind RCT, patients with CD who continued using their conventional CD med-
ication showed improvements when given a combination of Synergy 1 R© (6 g) and 2× 1011 CFU
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B. longum (Steed et al. 2010). Compared to a placebo, the synbiotic reduced TNF-α gene ex-
pression (P = 0.041), disease activity indexes (P = 0.02), and histological scores (P = 0.018)
after six months of treatment. The microbiota of tissue biopsies was analyzed in both a species-
and a genus-specific manner. Interestingly, 8 of 13 patients in the synbiotic group had increased
numbers of B. longum and bifidobacteria after three months compared to the baseline, and this in-
creased to 11 patients after six months. The nature of this responder/nonresponder phenomenon
was not addressed in the study.
Chermesh et al. (2007) investigated the potential of Synbiotic 2000 R© to prevent postopera-
tive recurrence of CD. This formulation contained Pediococcus pentoseceus, Lactococcus raffinolactis,
L. paracasei subsp. paracasei, and L. plantarum (each at 1× 1010 CFU) and 2.5 g each of β-glucan,
inulin, pectin, and resistant starch. The frequency of the treatment was not stated. The synbiotic
had no effect on endoscopic or clinical relapse or the postoperative occurrence of CD compared
to the placebo. However, it significantly improved weight gain and normalization of hemoglobin
levels by the three-month follow-up. No analysis of the gut microbiota was done.
Diarrhea
Diarrheal diseases are often caused by infectious agents, resulting in loose or liquid bowel move-
ments with increased frequency, water content, and volume. Worldwide, diarrhea is the leading
cause of hospitalizations, morbidity, and mortality (Dinleyici et al. 2013). A multistrain mixture of
Lactobacillus, Bifidobacterium, and Enterococcuswas combined with FOSs (626 mg) as a synbiotic and
was tested in children with acute diarrhea (Dinleyici et al. 2013). Treatment with oral rehydration
salts (ORSs) and intravenous therapy was also provided. Compared to a control group (receiving
only ORSs and/or intravenous therapy), the synbiotic shortened the duration of diarrhea (P <
0.0001) and the hospital stay (P = 0.002). The gut microbiota of these children was not analyzed.
In a similar study, children with acute rotavirus diarrhea were treated with species of Lac-
tobacillus, Streptococcus, and Bifidobacterium (1× 109 CFU total) and FOSs (990 mg) (Dewi et al.
2015). Standard fluid therapy and nutritional support were provided. Thirty-five children were
enrolled in the synbiotic group and compared to a placebo group. The duration of diarrhea was
significantly shorter in the synbiotic group (P < 0.0001), and for half of the patients receiving a
synbiotic treatment, intestinal mucosal healing was reported 50 hours after administration. The
gut microbiota was not analyzed. No further descriptions were given to explain why half of the
group responded to the treatment.
An arabinogalactan (500 mg) and xylooligosaccharide (700 mg) mixture was used to formulate
a synbiotic that also included L. paracasei B21060 (2.5× 109 CFU). Subjects included 55 children
with acute diarrhea, who receivedORS treatment. The synbiotic group showed a higher resolution
rate (P = 0.005) than the placebo group after the first 72 hours (Passariello et al. 2012). This
study allowed for additional treatments (e.g., diosmectite, domperidone, or racecadotril) given by
the parents after the first 72 hours, which may have influenced the total duration of diarrhea. No
analysis of the fecal microbiota was performed.
A combination of S. thermophilus, L. bulgaricus, Bifidobacterium animalis subsp. lactis, and inulin
(1 g) was assessed for its potential to prevent diarrhea, vomiting, and various infections in children
(Ringel-Kulka et al. 2015). After 16weeks of treatment, synbiotic-treated children had significantly
fewer days of fever but significantly more days with watery stools (P < 0.05). In this RCT, no
analysis of the microbiota or assessment of the effect of the individual components was performed.
GI symptoms, such as diarrhea, are frequently reported among HIV and AIDS patients. da
Silveira et al. (2017) tested the efficacy of FOSs (6 g) and a mixture of L. paracasei, L. rhamnosus,
L. acidophilus, and B. lactis compared to a maltodextrin placebo. Patients (n = 64) consumed
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treatments twice daily for 6 months together with a personalized eating plan. Both the synbiotic
and placebo groups had a significant reduction of diarrhea andwere not significantly different from
one another. An analysis of the gut microbiota was not conducted, and no specific explanation was
given as to why this synbiotic combination was selected.
Irritable Bowel Syndrome
IBS is an intestinal disorder characterized by abdominal pain, bloating, diarrhea, constipation,
or alternating periods of these symptoms. The cause of this illness has not been established, but
visceral hypersensitivity, genetics, the gut microbiota, constant low-grade inflammation, and envi-
ronment are contributing factors (Ford et al. 2014). Approximately 11% of the world’s population
may be affected by IBS, with higher occurrences among women and younger individuals (Canavan
et al. 2014, Endo et al. 2015). Physiological interventions, dietary manipulations, pharmacologic
agents, and modulation of the gut microbiota are part of current treatments for IBS (Gibson et al.
2015).
A recent study examined the effect of L. acidophilus (1.8× 107 CFU/g), B. animalis subsp. lactis
Bb-12 (2.5× 107 CFU/g), and Beneo dietary fibers (2%) on the quality of life and IBS symptoms
of 76 constipation-predominant IBS patients (Sˇmid et al. 2016). The synbiotic was delivered twice
daily in 180 g of fermented milk for 4 weeks. Several markers of IBS improved after four weeks,
but there was no difference between the synbiotic and the placebo (fermented milk) groups.
An RCT assessed the effect of L. acidophilus, B. animalis subsp. lactis, S. thermophilus, and dietary
fiber (90%inulin, 10%oligofructose) in fermentedmilk on thegutmicrobiota of 30 adults suffering
from IBS (Matijasˇic´ et al. 2016). According to real-time polymerase chain reaction and relative
afferent pupillary defect analyses of fecal samples, the presence of all three treatment bacteria
was confirmed in the synbiotic group and decreased at the one-week follow-up. There was no
significant difference detected in the abundance of the test bacteria within the synbiotic treatment
group; strains were not detected in the control group. The effect of the synbiotic treatment
on IBS symptoms was not assessed in this study. Finally, Cudmore et al. (2017) showed that a
synbiotic containing psylliumfiber, inulin,L. rhamnosus,B. bifidum,L. acidophilus,L. plantarum, and
L. bulgaricus significantly reduced the use of laxatives after a four-week treatment in adults with
chronic constipation.
Colon Cancer
Colorectal cancer is the third-most common form of cancer. In addition to genetic factors, envi-
ronmental factors such as radiation, chemical carcinogens, and diet contribute to tumorigenesis
in the colon (Willett 2000). Current treatments are associated with a high risk of complications
and low success rate. Investigators have suggested that by maintaining a healthy weight, diet, and
physical activity, up to one-third of colon cancers may be prevented (Raman et al. 2013). Numer-
ous pro-, pre-, and synbiotic studies using rodent models suggest that these treatments may have
preventive and therapeutic properties.
Rafter et al. (2007) andRoller et al. (2007) assessed a combination ofL. rhamnosusGG (LGGR©),
B. lactis Bb12, and Synergy 1 R© on colon cancer and polypectomized patients in two similar phase
II anticancer studies. The synbiotic treatment was compared to a placebo in a 12-week trial. Fecal
water obtained from the cancer patients did not improve barrier function in Caco-2 cells and in-
creased production of interferon-γ. For polypectomized patients, several benefits were observed
among the synbiotic group, including decreased DNA damage in colonic mucosa, reduced pro-
liferation, and decreased secretion of IL-2. The investigators also assessed survival of each of the
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probiotic strains in an independent study with healthy human subjects who consumed rifampicin-
resistant mutants of each strain (Rafter et al. 2007). After consumption of the probiotics, both
strains were isolated from feces by plating. For the study patients, a fecal analysis was performed
not at the strain level but at the genus level. The number of Lactobacillus and Bifidobacterium con-
sistently increased in the synbiotic group for both cancer and polypectomized patients over the
12-week trial, whereas Clostridium numbers decreased. As a probiotic-only treatment was not ap-
plied, a synergy between the probiotic strains and Synergy 1 R© could not be confirmed based on
these data. Roller et al. (2007) did not analyze the fecal microbiota but referred to another study
that reported that only 10% of the consumed amount of LGGR© and Bb12 survived the GI tract in
the same synbiotic treatment (Van Loo et al. 2005). Neither study analyzed the pro- and prebiotic
components independently.
In a four-week crossover trial, the effect of the synbiotic combination of resistant starch (12.5 g)
and B. lactis (5× 109 CFU) on markers of early colorectal carcinogenesis was investigated in
20 healthy subjects (Worthley et al. 2009). Placebo, prebiotic-only, and probiotic-only arms were
also included. Full analyses of the fecal microbiota were conducted using denaturing gradient gel
electrophoresis and quantitative real-time polymerase chain reaction to assess levels of B. lactis.
Results showed that the synbiotic treatment introduced significantly more changes to the gut
microbiota than the placebo or the pro- or prebiotic treatments alone. However, levels of B. lactis
in the probiotic and synbiotic treatment groups were not significantly different. No differences
were detected for the SCFA profile, fecal ammonia or pH, serum inflammatory markers, or
epithelial variables among the treatment groups.
Kidney and Liver Disease
Approximately 6–10% of adults suffer from varying degrees of chronic kidney disease ( Jha et al.
2013), and the prevalence of NAFLD ranges between 6.3% and 33% (Charytoniuk et al. 2017).
Both pro- and prebiotics have been suggested as possible therapies for these conditions (Koppe
et al. 2015, Lambert et al. 2015, Vitetta & Gobe 2013). Recently, several synbiotic clinical trials
for kidney and liver disease have been described. A synbiotic containing a nine-strain cocktail
(bifidobacteria, lactobacilli, and streptococci) and a FOS/GOSmixturewas given to chronic kidney
disease patients (Rossi et al. 2016). Most of the measured biomarkers in this small study (n = 31)
were unchanged by the treatment, althoughmicrobiota analyses revealed an increase in abundance
of bifidobacteria and depletion of Ruminococcaceae. A combination of B. longum with FOSs was
also used for treatment of liver disease (Malaguarnera et al. 2007, 2012). Although improvements
in immune biomarkers and liver function were observed in both studies, the microbiota was not
assessed and individual components were not included as controls.
The effect of a seven-strain mix containing species of Lactobacillus, Streptococcus, and Bifidobac-
terium (2× 108 CFU total) and FOSs (125 mg) was tested on 50 NAFLD patients (Mofidi et al.
2017). This RCT showed that the synbiotic group had a greater reduction of steatosis and fibro-
sis. Similarly, the same synbiotic cocktail improved the steatosis grade in an RCT involving 80
NAFLD patients but did not improve levels of alanine aminotransferase and aspartate transami-
nase compared to a placebo (Asgharian et al. 2016). The same cocktail plus vitamin E decreased
the concentrations of liver transaminase and led to significant differences in total cholesterol and
LDL cholesterol compared to the control groups (Ekhlasi et al. 2016).
Finally, there are several other published studies on synbiotics to treat the various diseases
described above, but these are not included in this discussion due to their absence of suitable or
appropriate controls (Andriulli et al. 2008, Basturk et al. 2016, Colecchia et al. 2006, Dughera
et al. 2007, Fujimori et al. 2007, Rossi et al. 2015), very low patient numbers (Fernandes et al.
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2016), or lack of evidence of effectiveness (Cruz-Mora et al. 2014, Garcı´a-Menor et al. 2016, Virk
et al. 2013).
COMMERCIAL SYNBIOTICS: OBSTACLES, CHALLENGES,
AND FUTURE PROSPECTS
By 2018, the global market for probiotics is predicted to exceed $40 billion (Buriti et al. 2016),
and the prebiotic market may soon reach $5 billion (Belorkar & Gupta 2016). Despite these
market opportunities, however, several scientific and industrial barriers exist (Van denNieuwboer
et al. 2016). In particular, Van denNieuwboer et al. (2016) suggested that the main barrier was the
“difficulty in demonstrating clinical efficacy.” This situation is complicated by the level of evidence
required to support a health claim, which varies from country to country (Van Loveren et al.
2012). Currently, neither the EFSA nor the FDA has approved any health claim made for pro- or
synbiotic combinations.Moreover, such productsmust be distinguished as either a pharmaceutical
product or a food product (Govender et al. 2014). The FDA guidelines state that if any agent,
including probiotics, is ingested for the purpose of curing, mitigating, treating, diagnosing, or
preventing disease, it is classified as a drug and must undergo the same regulatory process as any
new pharmaceutical. The European Union Nutrition and Health Claims regulations intend to
(a) ensure that claims are “clear, accurate and based on scientific evidence” and (b) prohibit foods
that bear “claims that could mislead consumers.” Ultimately, high-quality human-intervention
studies are necessary to support any health claims made for a product (Van Loveren et al. 2012).
Synbiotic products are commonly delivered to consumers in food form, including a range of
cultured dairy and nondairy products. Although prebiotics can be used in most food applica-
tions, the environmental sensitivity of probiotics (and synbiotics) may limit their practical use in
many nonrefrigerated foods (Saulnier 2008). However, newmicroencapsulation technologies that
protect the bacteria against otherwise detrimental processing treatments could lead to a variety
of new synbiotic products, including desserts, confections, juices, cheeses, or chocolate (Ahmadi
et al. 2014, Angiolillo et al. 2014, Konar et al. 2016, Fratianni et al. 2014, Petreska-Ivanovska et al.
2014). Interestingly, many pre- and synbiotic products contain small amounts of the prebiotic
component (on a per serving basis), which may be too low to induce a health effect. Low doses are
used, in part, to avoid adverse GI complaints (De Vrese & Schrezenmeir 2008) but perhaps also
for reasons of cost.
The development of clinically effective synbiotic combinations remains a challenging issue,
and several requirements must be satisfied. As noted above, determining minimum effective doses
of each component is usually expected. The inclusion of suitable controls for synbiotic trials is
particularly challenging. Apart from standard placebo controls, probiotic-only and prebiotic-only
controls may also be necessary to confirm additive or synergistic effects. The rationale for how the
pro- and prebiotic were selected and combined should also be stated. Importantly, demonstrating
causality requires specific detection, quantification, and enrichment of the test strain in theGI tract.
Changes introduced to the gut microbiota should also be assessed to determine whether cross-
feeding or other ecological events occurred, for example, niche competition, niche partitioning,
or niche exclusion with the resident microbiota.
CONCLUDING REMARKS
Disturbances of the microbial composition in the GI tract have been associated with deterioration
of host health and barrier, immune, and other functional activities. These developments may
either be directly induced by the gut microbiota or via an altered metabolite synthesis ( Jonkers
www.annualreviews.org • Synbiotics for Improved Human Health 469
FO09CH20_Hutkins ARI 9 February 2018 11:7
2016). Although the microbiota composition in the human GI tract is remarkably stable, it can be
successfully modulated by certain synbiotic treatments. These treatments could offer considerable
advantages to human health when selected on a rational basis that accounts for ecological and
evolutionary considerations.
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